News

6 August 2021

Cambridge Cognition: COVID-19 Update

We would like to update you on the steps Cambridge Cognition is taking to ensure business continuity for all our customers as the widespread impact of COVID-19 (coronavirus) continues to affect so many globally.

Read on

1 July 2021

Spin-out of Monument Therapeutics

Cambridge Cognition is pleased to announce the completion of the spin-out of Monument Therapeutics, a drug development company applying digital phenotyping to central nervous system ("CNS") disorders.

Read on

28 June 2021

New £2.2 million contract for at-home cognitive testing in a virtual clinical trial

Cambridge Cognition has been selected as the cognitive assessment partner for a large at-home study. The contract is valued at £2.2 million with revenue expected to be recognised by the Company over three years beginning in H2 2021.

Read on

11 June 2021

Cambridge Cognition to join the Brain Health Registry as cognitive assessment partner

Cambridge Cognition Holdings is pleased to announce that it will be joining the University of California, San Francisco (UCSF) Brain Health Registry as a cognitive assessment partner. The Brain Health Registry is an online platform designed to speed up the discovery of treatments for Alzheimer's disease, Parkinson's disease, depression, post-traumatic stress disorder, and other brain disorders.

Read on

26 April 2021

Cognition and COVID-19: CANTAB Research Grant - Results

The results of the 2021 CANTAB Research Grant are in! This year's award was focussed on the connection between cognition and COVID-19.

Read on

8 April 2021

Cambridge Cognition provides cognitive assessments in an at-home clinical trial

Cambridge Cognition has won a contract with a new pharmaceutical client to provide cognitive assessments in an at-home clinical trial. The contract is worth approximately £0.5 million.